NLA Recommendations & Statements

The NLA released an official scientific statement on Lipoprotein(a) [Lp(a)] designed as a comprehensive source of guidance for medical professionals making decisions to improve the health and well-being of children and adults at risk of premature cardiovascular disease.

The NLA has released a statement paper that provides updated guidance to clinicians to help identify patient groups in whom treatment with PCSK9 monoclonal antibodies (mAbs) provides a reasonable value.

This  document  was  approved  by  the  American  College  of  Cardiology  Clinical  Policy  Approval  Committee,  the American Heart Association Science Advisory and Coordinating Committee, American Association of Cardiovascular and Pulmonary  Rehabilitation,  American  Academy  of  Physician  Assistants,  Association  of  Black  Cardiologists, American  College  of  Preventive  Medicine,  American  Diabetes  Association,  American  Geriatrics  Society,  American Pharmacists  Association,  American  Society  for  Preventive  Cardiology,  National  Lipid  Association,  and  Preventive Cardiovascular  Nurses  Association  in  October 2018,  and  the  American  Heart  Association  Executive  Committee  in  October 2018.

https://www.lipid.org/nla/national-lipid-association-releases-draft-part-two-its-recommendations-patient-centered The NLA Recommendations for Patient-Centered Management of Dyslipidemia, published in the Journal of Clinical Lipidology, re-affirm the importance of cholesterol goals for the prevention of heart attack and stroke. The recommendations should serve as guidance to clinicians for treating patients with dyslipidemia.

On June 3, 2015, the anticipated final results of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) was published online in the New England Journal of Medicine (NEJM 2015;372:2387-97).

The National Lipid Association (NLA) recently convened an Expert Panel on Statin Safety to examine various aspects of statin therapy and to determine its safety, patient tolerance and effectiveness.

The NLA held a consensus conference in January 2011 to bring together experts on inflammatory markers and advanced lipoprotein testing for the generation of an NLA statement of clinical guidance regarding the utility of various biomarkers. The panel reviewed apolipoprotein B (Apo B), C-reactive protein (CRP), high-density lipoprotein (HDL) subfractions, lipoprotein-associated phospholipase A2 (Lp-PLA2), low-density lipoprotein (LDL) subfractions, low-density lipoprotein particle number/concentration (LDL-P), and lipoprotein (a) (Lp(a)).

Adapted from an article in the Journal of Clinical Lipidology (JCL) titled, The Importance of Non-HDL Cholesterol Reporting in Lipid Management¹

In connection with the Familial Hypercholesterolemia ("FH") initiative of the Foundation of the National Lipid Association, the NLA held a consensus conference in January 2011 to bring together experts on FH for the generation of an NLA statement of clinical guidance regarding the diagnosis and treatment FH. The link above provides the Executive Summary of the NLA expert panel, published in the June 2011 edition of the Journal of Clinical Lipidology.